Get started
Clinuvel Pharmaceuticals Ltd.Clinuvel Pharmaceuticals Ltd.Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastSeasonals

CLVLY chart


Full chart

CLVLY upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪377.06 M‬ USD
Dividend yield (indicated)
0.35%
Price to earnings Ratio (TTM)
16.89
Basic EPS (TTM)
0.47 USD
Net income (FY)
‪23.43 M‬ USD
Revenue (FY)
‪61.54 M‬ USD
Shares float
—
Beta (1Y)
0.73

About Clinuvel Pharmaceuticals Limited


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Lachlan Hay
Website
clinuvel.com
Headquarters
Melbourne
Founded
1999
ISIN
US1887691038
FIGI
BBG000FL1WL1
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

Check out other big names from the same industry as CLVLY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CLVLY news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.